The reiteration of a Buy rating combined with an increased price target from $3 to $5 by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for Sangamo Therapeutics. This suggests confidence in the company's future performance and potential for growth, likely leading to increased investor interest and a positive short-term impact on the stock price.